Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication
Status:
Unknown status
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
Patients infected and living with HIV are getting older and have more and more non-HIV
co-morbidities. These expose them to polypharmacy that increases the risk of pharmacological
interaction. Bictegravir, co-formulated with emtricitabine (FTC) and tenofovir alafenamide
(TAF) (BIKTARVY) a new generation integrase inhibitor with a high genetic barrier and had no
drug interaction may be a treatment of choice for participant over 65 years old who are HIV
infected . BIKTARVY improve adherence and quality of life; and on the other hand it would
limit the risks of pharmacological interaction. In addition, the use of TAF reducing the risk
of long-term renal toxicity and adverse effects on bone would be of interest in this aging
population and more at risk of osteoporosis.
Phase:
Phase 4
Details
Lead Sponsor:
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba